Esophageal squamous cell carcinoma (SCC) is a common malignant tumor in the digestive tract and its incidence among the Chinese population ranks first in the world. The prognosis of esophageal SCC is very poor, mainly because severe invasion and lymph node metastases have already occurred by the time the disease is diagnosed. Thus, most patients being treated for esophageal SCC are at an advanced stage. Strikingly, the 5-year survival rate of patients with early stage esophageal SCC is up to 80%-90%, whereas that of patients with advanced stage esophageal SCC is less than 30%. Thus, it is of great significance to explore selective biomarkers that are able to predict the prognosis of esophageal SCC and further guide clinical treatment.

Cancer invasion and metastasis require degradation of the extracellular matrix and connective tissues surrounding the tumor. Laminins are a family of extracellular matrix proteins localized at the basement membrane and are involved in cell adhesion, migration, proliferation, and differentiation. Laminin-5 belongs to the laminin family and is a hetero-trimeric glycoprotein composed of α~3~, β~3~, and γ~2~ subunits. The γ~2~ chain is unique to laminin-5[@b1]. The secreted protein acidic and rich in cysteine (SPARC) is one of the non-structural matricellular proteins. SPARC mediates the interaction of the matrix with the cell, but does not participate in the structural formation of the extracellular matrix[@b2]. Whether they are involved in extracellular matrix formation and stabilization differentiates extracellular matrix proteins such as laminin-5 γ~2~ from matricellular proteins such as SPARC. Both laminin-5 γ~2~ chain and SPARC are overexpressed in many types of cancers and play important roles in tumorigenesis and cancer progression. Therefore, these proteins are of clinical significance to predict the prognosis of advanced cancers. It has been reported that the expression levels of laminin-5 γ~2~ chain are significantly higher in gastric cancer, head and neck cancer, tongue cancer, colon cancer, breast cancer, cervical cancer, and skin cancer than in corresponding normal tissues and that the overexpression of laminin-5 γ~2~ chain is predominantly observed in the cytoplasm of carcinoma cells at the invasive front. The expression and function of SPARC in human cancer tissues is more complicated and depends on cancer type and cellular microenvironment. SPARC is highly expressed in breast cancer, colon cancer, gastric cancer, bladder cancer, liver cancer, and prostate cancer. In addition to cancer cells, stromal cells, usually fibroblasts, also express SPARC. Although the expressions of laminin-5 γ~2~ chain and SPARC have been extensively studied in the above-mentioned cancers[@b3]--[@b8], their expressions in advanced esophageal SCC and its significance in prognosis are still unclear. Yamamoto *et al.*[@b9] reported the expression of laminin-5 γ~2~ chain in esophageal cancer is related to the age, gender, invasion degree (only a trend without statistical difference), lymph node metastasis, and pTNM stage. In addition, the high expression of laminin-5 γ~2~ chain appeared to be linked with poor prognosis. Yamashita *et al.* [@b10] demonstrated the localization of SPARC protein in both cancer cells and stromal cells of esophageal cancer using immunohistochemistry. However, they didn\'t do statistical analysis of the relation between SPARC protein expression and prognosis, owing to a small number of patients. Instead, Northern blot hybridization suggested the expression of SPARC mRNA is related to lymph node metastasis and poor prognosis. With such a paucity of findings, the expression and role of both laminin-5 γ~2~ chain and SPARC in advanced esophageal SCC warrant further investigation.

The laminin-5 γ~2~ chain has been reported degraded by matrix metalloproteinase (MMP) secreted from cancer cells or adjacent stromal cells, resulting in an increased capacity of migration and/or invasion in cancer cells. Thus, laminin-5 γ~2~ chain may serve as an effective target during cell migration and invasion[@b11]. Overexpression of laminin-5 γ~2~ chain increases cell proliferation, and thereby promotes tumor growth[@b12]. In contrast, SPARC increases the expression of MMP in fibroblasts and monocytes. Since MMP enhances tumor cell degradation of the extracellular matrix, its overexpression enhances cell movement and is strongly related to cancer invasion, metastasis and prognosis[@b13]--[@b18]. Therefore, it is intriguing to suppose that laminin-5 γ~2~ chain and SPARC have a synergistic effect in tumor progression and metastasis. Moreover, SPARC has been shown to interact directly with laminin, and its expression is related to laminin production [@b19]--[@b21]. It is possible that SPARC potentiates cancer progression and metastasis through its ability to enhance laminin expression. However, the relationship between the γ~2~ chain of laminin and SPARC has not yet been fully studied.

The present study aimed to detect the expressions of laminin-5 γ~2~ chain and SPARC in advanced esophageal SCC using tissue microarray based on immunohistochemistry and to determine their correlation with clinicopathologic characteristics and survival of patients. In addition, we also investigated the relationship between the expressions of laminin-5 γ~2~ chain and SPARC to clarify their synergic effect on the progression of esophageal SCC.

Patients and Methods {#s2}
====================

Patients and sample collection {#s2a}
------------------------------

Specimens were collected from 116 cases of esophageal SCC. All the patients had undergone curative surgical resection at Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences between June 2001 and June 2002. No preoperative radiotherapy or chemotherapy was performed for all of these patients. Of the 116 patients, 94 were male and 22 were female, aged ranging from 33 to 78 years, with a median age of 59.5. The carcinoma tissue and the corresponding normal mucosa were fixed with 80% ethanol and embedded in paraffin. Of the 116 esophageal SCC, 31 were well differentiated, 56 were moderately differentiated, and 29 were poorly differentiated. The clinicopathologic characteristics of all patients were evaluated according to the guidelines of International Union Against Cancer (UICC) 2002 pTNM criteria. Of the 116 cases, 43 were at stage MA, 11 were at stage NB, 53 were at stage III, and 9 cases were at stage IV.

Follow-up {#s2b}
---------

Survival time was defined as the time from surgery to death or the last follow-up visit. Patients dying of serious complications during surgery, of causes other than esophageal SCC, or in less than 3 months after surgery were not included. The longest survival time was 89 months by the last follow-up visit, and the median survival time is 36 months.

Construction of tissue microarray {#s2c}
---------------------------------

Representative areas containing morphologically representative SCC and regions of normal mucosa were constructed on donor paraffin blocks based on hematoxylin and eosin (HE) staining. The appropriate tissues were constructed on receptor paraffin blocks using a tissue microarrayer (Beecher Instruments, Silver Spring, MD, 0.6 mm in diameter of cores)[@b22],[@b23]. Each case of SCC and corresponding normal mucosa were loaded twice to ensure representation of the chip and to avoid missing information due to loss of tissue cores.

Immunohistochemistry assay and data analysis {#s2d}
--------------------------------------------

A standard streptavidin-peroxidase conjugated method (SP) was used for immunohistochemistry assay. Slides were de-waxed in xylene and hydrated through gradient ethanol to distilled water. Subsequently, antigen retrieval was performed as follows. For laminin-5 γ~2~ chain, slides were incubated with protease XXIV (Biogenex, USA) at room temperature for 10 min. For SPARC, slides were microwaved in 0.01 mol/L citrate buffer (pH 6.0) for 10 min. Slides were then incubated with 3% H~2~O~2~ for 10 min to block endogenous peroxidase, blocked in 10% normal goat serum for 10 min to reduce non-specific staining and incubated with 1:50 dilutions of primary antibodies against laminin-5 γ~2~ chain (mouse monoclonal antibody, Chemicon, USA) and against SPARC (mouse monoclonal antibody, Novacastra, UK) at room temperature for 1 h. Slides were washed three times with PBS and incubated with biotinylated anti-mouse secondary antibodies for 10 min at room temperature followed by incubation with horseradish peroxidase streptavidin at room temperature for 10 min. After DAB staining, slides were counter-stained with hematoxylin. PBS was used to replace primary antibodies as a negative control.

Scoring criteria for expression of laminin-5 γ~2~ chain is as follows: negative (-), no laminin-5 γ~2~ positive cells; weakly positive (+), less than 30% cells are laminin-5 γ~2~ positive; and strongly positive (++), more than 30% of cells are laminin-5 γ~2~ positive[@b24]. Different scoring criteria for SPARC were used for stromal cells and cancer cells/normal cells. Scoring criteria for stromal cells is as follows: negative (-), no fibroblasts are SPARC positive; weakly positive (+), less than 50% of fibroblasts are SPARC positive; and strongly positive (++), more than 50% of fibroblasts are SPARC positive[@b2]. Scoring criteria for cancer/normal epithelial cells is as follows: negative (-), no cells are SPARC positive; weakly positive (+), SPARC positive cells are less than 30%; and strongly positive (++), SPARC positive cells are more than 30%. The intensity of immunostaining is comparable within all of the cases for both proteins; however, the percentage of immuno-positive cells is significantly different. Therefore, we only considered the percentage of immuno-positive cells for data analysis.

Groupings {#s2e}
---------

To determine the role of laminin-5 γ~2~ chain and SPARC in the progression of esophageal SCC, we divided 116 cases into two groups. Group A includes cases at stages NA and NB, while group B includes cases at stages III and IV. To determine the significance of elevated co-expression of laminin-5 γ~2~ chain and SPARC, we divided the 116 cases into three groups: in group one, neither laminin-5 γ~2~ chain nor SPARC is highly expressed; in group two, either laminin-5 γ~2~ chain or SPARC is highly expressed; and in group three, both laminin-5 γ~2~ chain and SPARC are highly expressed. Group A is further categorized into three subgroups: group A1 consists of cases in which neither laminin-5 γ~2~ chain nor SPARC highly expressed, group A2 consists of cases in which either laminin-5 γ~2~ chain or SPARC highly expressed, and group A3 consists of cases in which both laminin-5 γ~2~ chain and SPARC highly expressed.

Statistical analysis {#s2f}
--------------------

SPSS16.0 statistical software was used for statistical analysis. The χ^2^ test or Fisher\'s exact test was utilized to analyze the relationship between laminin-5 γ~2~ chain and SPARC expressions in cancer tissue and the Clinicopathological characteristics. Spearman rank correlation coefficient was calculated to determine the correlation between these two proteins. Furthermore, the Kaplan-Meier survival analysis with log-rank test was performed to analyze the relationship between the expression levels of the two proteins in cancer tissue or other clinicopathologic characteristics and the survival rate of patients. A value of *P* \< 0.05 was defined as significantly different.

Results {#s3}
=======

Expressions of laminin-5 γ~2~ chain and SPARC in SCC and normal mucosa {#s3a}
----------------------------------------------------------------------

In squamous cells of normal esophageal mucosa, laminin-5 γ~2~ was localized at the basement membrane but not in the cytoplasm. In contrast, laminin-5 γ~2~ was expressed in the cytoplasm of cancer cells, predominating in cells at the invasive front of the tumor. Of the 116 cases, 66 (56.9%) were weakly positive and 18 (15.5% ) were strongly positive for laminin-5 γ~2~ expression. SPARC was not expressed in normal esophageal epithelium or stromal cells in lamina propria, but was strongly expressed in SCC stromal fibroblasts. Six cases had tumor nests without any visible stromal cells in the tissue microarray. Of the remaining 110 cases that contained stromal cells, 32 (29.1%) were weakly positive and 61 (55.5%) were strongly positive. Only 9 cases (7.8%) showed SPARC positive in the cytoplasm of cancer cells at the invasive front of tumor nests, which included 4 weakly positive cases and 5 strongly positive cases ([Figure 1](#cjc-30-01-069-g001){ref-type="fig"}).

The relationship between the expression levels of laminin-5 γ~2~ chain and SPARC and clinicopathologic characteristics of SCC {#s3b}
-----------------------------------------------------------------------------------------------------------------------------

Laminin-5 γ~2~ expression was associated with the degree of cancer differentiation, being highly expressed in moderately differentiated and poorly differentiated carcinomas (*P* = 0.004) ([Table 1](#cjc-30-01-069-t01){ref-type="table"}). However, SPARC expression in stromal cells and cancer cells did not exhibit any correlation with clinicopathologic characteristics (*P* \> 0.05) ([Table 2](#cjc-30-01-069-t02){ref-type="table"}).

The relationship between laminin-5 γ~2~ chain and SPARC expression {#s3c}
------------------------------------------------------------------

The expression of laminin-5 γ~2~ chain increased as the expression of SPARC in stromal fibroblasts increased (Spearman correlation coefficient is 0.423, *P* \< 0.001). However, the expression level of laminin-5 γ~2~ chain was not associated with SPARC expression level in cancer cells (Spearman correlation coefficient is -0.100, *P* = 0.287) ([Table 3](#cjc-30-01-069-t03){ref-type="table"}).

Overall survival analysis {#s3d}
-------------------------

The 5-year survival rate of the 116 patients in this study was 41.7%. The Kaplan-Meier survival analysis showed that age, lymph node metastasis, invasive depth, pTNM stage, the expression levels of laminin-5 γ~2~ chain and SPARC in stromal cells were related to the survival rate (*P* = 0.002, *P* = 0.002, *P* \< 0.001, *P* \< 0.001, *P* = 0.032, and *P* = 0.034, respectively). As shown in [Figure 2A--D](#cjc-30-01-069-g002){ref-type="fig"}, the 5-year survival rate of patients with strongly positive laminin-5 γ~2~ chain expression was 22.2%, whereas that of patients with negative and weakly positive laminin-5 γ~2~ expression was 45.5%. The 5-year survival rate of patients with strongly positive SPARC expression in stromal cells was 32.7%, whereas that of patients with negative and weakly positive SPARC expression was 52.0%. The 5-year survival rate of patients with positive SPARC expression in cancer cells was 37.5%, while that of patients with negative SPARC expression was 42% (*P* = 0.944).

Survival analysis of group A and group B {#s3e}
----------------------------------------

For the patients within group A (stage IIA/IIB), the expression level of laminin-5 γ~2~ chain was significantly correlated with the survival rate (*P* = 0.023). The 5-year survival rate of patients with strong expression was 33.3%, while that of patients with negative and weakly positive expression of laminin-5 γ~2~ chain was 72.1%. For patients in group B (stage III/IV), the expression level of laminin-5 γ~2~ chain was not significantly related to the survival rate (*P* = 0.844). The 5-year survival rate of patients with strongly positive laminin-5 γ~2~ chain expression was 16.7%, while that of patients with negative and weakly positive expression was 17.8%. In group A, the 5-year survival rate of patients with strongly positive SPARC expression in stromal cells was 56.7%, which was not statistically different from that of patients with negative and weakly positive SPARC expression (75.0%)(*P* = 0.154). In group B, the 5-year survival rate of patients with strongly positive SPARC expression in stromal cells was 18.9%, while that of patients with negative and weakly positive SPARC expression was 16.7% (*P* = 0.988). The survival rate of patients with positive SPARC expression in cancer cells was not investigated owing to the paucity of cases ([Figure 2E-H](#cjc-30-01-069-g002){ref-type="fig"}).

Survival analysis of co-expression laminin-5 γ~2~ chain and SPARC {#s3f}
-----------------------------------------------------------------

Patients were divided into 3 groups according to the expression of laminin-5 γ~2~ chain and SPARC as described in the method section. Patients in group three, with a strong expression of laminin-5 γ~2~ chain and SPARC, had a 5-year survival rate of 7.7%, while patients in group one, without strong expression of laminin-5 γ~2~ chain or SPARC, had a 5-year survival rate of 51.0% and patients in group two, with strong expression of either laminin-5 γ~2~ chain or SPARC, had a 5-year survival rate of 41.9%. There was significant difference among these three groups (*P* = 0.001), as shown in [Figure 2I](#cjc-30-01-069-g002){ref-type="fig"}. In patients with stage-IIA/IIB esophageal SCC, the 5-year survival rate of the A3 subgroup, which strongly expressed laminin-5 γ~2~ chain and SPARC, was 0, while the 5-year survival rate of the A1 subgroup and the A2 subgroup was 73.1% and 73.3%, respectively. The 5-year survival rates of the three subgroups were significantly different (*P* \< 0.001), as shown in [Figure 2J](#cjc-30-01-069-g002){ref-type="fig"}.

![Immunohistochemistry for laminin-5 γ~2~ chain and SPARC in esophageal squamous cell carcinoma (SCC). A, laminin-5 γ~2~ chain is strongly expressed in the basement membrane of normal esophageal epithelia. B, laminin-5 γ~2~ chain was not detected in esophageal SCC. C, laminin-5 γ~2~ chain is weakly expressed in the cytoplasm of esophageal SCC, mainly at the tumor-stroma interface. D, laminin-5 γ~2~ chain is strongly expressed in the cytoplasm of esophageal SCC, mainly at the tumor-stroma interface. E, SPARC was not detected in the epithelia or lamina propria mucosa stroma of normal mucosa. F, SPARC was not detected in the cancer cells or stromal fibroblasts in esophageal SCC, with expression only exhibiting in the endothelia of small vessels. G, SPARC is weakly expressed in stromal fibroblasts in esophageal SCC but was not detected in cancer cells. H, SPARC is strongly expressed in stromal fibroblasts in esophageal SCC but was not detected in cancer cells. *Bar*, 100 µm.](cjc-30-01-069-g001){#cjc-30-01-069-g001}

###### Correlation between laminin-5 γ~2~ chain expression and clinicopathologic characteristics in 116 patients with esophageal squamous cell carcinoma

  Clinicopathologic characteristic    No. of patients   Laminin 5 γ~2~ expression (*n* = 116)    *P*^a^              
  ---------------------------------- ----------------- --------------------------------------- ---------- ---------- -------
  Age (years)                                                                                                         0.745
   ≥ 60                                     58                        15(25.9)                  35(60.3)   8(13.8)   
   \< 60                                    58                        17(29.3)                  31(53.4)   10(17.2)  
  Gender                                                                                                              0.296
   Male                                     94                        23(24.5)                  56(59.6)   15(16.0)  
   Female                                   22                         9(40.9)                  10(45.5)   3(13.6)   
  Differentiation                                                                                                     0.004
   Well                                     31                         8(25.8)                  21(67.7)    2(6.5)   
   Moderate                                 56                         9(16.1)                  35(62.5)   12(21.4)  
   Poor                                     29                        15(51.7)                  10(34.5)   4(13.8)   
  Invasive depth (T)                                                                                                  0.592
   T1/2                                     22                         8(36.4)                  11(50.0)   3(13.6)   
   T3/4                                     94                        24(25.5)                  55(58.5)   15(16.0)  
  Lymph node metastasis (N)                                                                                           0.386
   N0                                       49                        15(30.6)                  29(59.2)   5(10.2)   
   N1                                       67                        17(25.4)                  37(55.2)   13(19.4)  
  pTNM stage                                                                                                          0.286
   IIA/IIB                                  54                        18(33.3)                  30(55.6)   6(11.1)   
   III/IV                                   62                        14(22.6)                  36(58.1)   12(19.4)  

Data are presented as numbers, with percentages in parentheses.

^a^ *P* values among −, + and ++ groups by χ^2^ test.

###### Correlation between SPARC expression and clinicopathologic characteristics in 116 esophageal esophageal squamous cell carcinoma patients

  Clinicopathologic characteristic    SPARC expression in stromal fibroblasts (*n* = 110)^a^    *P*^b^    SPARC expression in cancer cells (*n* = 116)    *P*^c^                        
  ---------------------------------- -------------------------------------------------------- ---------- ---------------------------------------------- ---------- ---------- --------- -------
  Age (years)                                                                                                                                             0.682                          0.162
   ≥ 60                                                      7(13.0)                           15(27.8)                     32(59.3)                                51(87.9)   7(12.1)  
   \< 60                                                     10(17.9)                          17(30.4)                     29(51.8)                                56(96.6)   2(3.4)   
  Gender                                                                                                                                                  0.191                          1.000
   Male                                                      12(13.5)                          24(27.0)                     53(59.6)                                86(91.5)   8(8.5)   
   Female                                                    5(23.8)                           8(38.1)                      8(38.1)                                 21(95.5)   1(4.5)   
  Differentiation                                                                                                                                         0.128                          0.368
   Well                                                       2(6.9)                           8(27.6)                      19(65.5)                                29(93.5)   2(6.5)   
   Moderate                                                  8(15.1)                           13(24.5)                     32(60.4)                                53(94.6)   3(5.4)   
   Poor                                                      7(25.0)                           11(39.3)                     10(35.7)                                25(86.2)   4(13.8)  
  Invasive depth (T)                                                                                                                                      0.571                          0.065
   T1/2                                                      5(22.7)                           6(27.3)                      11(50.0)                                18(81.8)   4(18.2)  
   T3/4                                                      12(13.6)                          26(29.5)                     50(56.8)                                89(94.7)   5(5.3)   
  Lymph node metastasis (N)                                                                                                                               0.142                          0.299
   N0                                                        8(17.8)                           17(37.8)                     20(44.4)                                47(95.9)   2(4.1)   
   N1                                                        9(13.8)                           15(23.1)                     41(63.1)                                60(89.6)   7(10.4)  
  pTNM stage                                                                                                                                             0.080^d^                        0.743
   IIA/IIB                                                   9(18.0)                           19(38.0)                     22(44.0)                                49(90.7)   5(9.3)   
   III/IV                                                    8(13.3)                           13(21.7)                     39(65.0)                                58(93.5)   4(6.5)   

Data are presented as numbers, with percentages in parentheses.

^a^ Of 116 cases, 6 had tumor nests without any visible stromal cells in the tissue microarray.

^b^ *P* values among −, + and ++ groups by χ^2^ test.

^c^ *P* values between −/+ and ++ groups by χ^2^ test.

^d^ *P* = 0.027 between −/+ and ++ groups.

###### The correlation between laminin-5 γ~2~ chain expression and SPARC expression

  Laminin-5 γ~2~ chain expression    SPARC expression in stromal fibroblasts^a^              SPARC expression in cancer cells^b^                         
  --------------------------------- -------------------------------------------- ---------- ------------------------------------- -- ---------- -------- ---------
  −                                                   11(37.9)                    12(41.4)                 6(20.7)                    27(84.4)   3(9.4)   2(6.3)
  \+                                                   6(9.5)                     15(23.8)                42(66.7)                    64(97.0)   1(1.5)   1(1.5)
  ++                                                    0(0)                      5(27.8)                 13(72.2)                    16(88.9)    0(0)    2(11.1)

Data are presented as numbers, with percentages in parentheses.

^a^ The expression of laminin-5 γ~2~ chain increased as the expression of SPARC in stromal fibroblasts increased (Spearman\'s rho = 0.423, *P* \< 0.001); ^b^ the expression level of laminin-5 γ~2~ chain was not associated with SPARC expression level in cancer cells (Spearman\'s rho = −0.100, *P* = 0.287).

Discussion {#s4}
==========

Laminins are a family of extracellular matrix proteins localized at the basement membrane and are involved in cell adhesion, migration, proliferation, and differentiation. Laminin-5 is a hetero-trimeric glycoprotein composed of α~3~ and β~3~ chains with a unique γ~2~ chain, which are products of LAMA3, LAMB3, and LAMC2 genes, respectively[@b1]. Laminin-5 γ~2~ chain is highly expressed in some malignant carcinomas such as gastric cancer, tongue cancer, colon cancer, cervical cancer, and malignant melanoma. In addition, its high expression is associated with cancer invasion, metastasis, and prognosis[@b25].

Laminin-5 γ~2~ chain was found localized at the basement membrane of normal esophageal mucosa and was expressed in the cytoplasm of cancer cells near the edge of esophageal SCC nests. Of 116 patients, 66 tested weakly positive and 18 tested strongly positive for laminin-5 γ~2~ chain expression. The percentage of positive cells was more than 30% in strongly positive group. So 15.5% (18/116) of the cases were positive for laminin-5 γ~2~ chain expression in more than 30% of the carcinoma cells. The positive ratio was slightly less than that reported by Yamamoto *et al*.[@b9], in which 44% of the cases were positive for laminin-5 γ~2~ chain expression in more than 30% of the carcinoma cells at the invasive front of esophageal SCC, possibly due to the differences in tissue sources, with tissue microarray employed in our study and traditional sections employed in their study. Most of tumors strongly expressing laminin-5 γ~2~ chain grew in cords or small nests, exhibiting typical growing patterns in poorly differentiated SCC. In contrast, tumors weakly or not expressing laminin-5 γ~2~ chain grew in large nests or large sheets, which are common in well-differentiated SCC. These observations are consistent with the conclusion that the expression of laminin-5 γ~2~ chain was related to tumor differentiation.

It has been reported that the ability of cancer cell to migrate and invade is enhanced when laminin-5 γ~2~ chain is cleaved by MMP, such as MMP-2 and/or MT1-MMP, secreted from cancer cells or adjacent stromal cells. Therefore, laminin-5 γ~2~ chain may be an effective target during cell migration and invasion[@b11]. In addition, cytoplasmic accumulation of laminin-5 γ~2~ chains may disrupt the synthesis of other laminin proteins, facilitating an increased capacity for cancer cell invasion[@b25]. Finally, studies have suggested overexpression of laminin-5 γ~2~ chain increased cell proliferation, thereby promoting tumor growth[@b12]. In the present study, we observed the expression of laminin-5 γ~2~ chain was not related to invasive depth, lymph node metastasis, or pTNM stage, but was an indicator of poor prognosis as revealed by survival analysis.

Matricellular proteins include a group of non-homologous molecules regulating the interaction of cells with the extracellular matrix. Matricellular proteins are different from extracelluar matrix proteins such as laminin due to lacking of participation in extracellular matrix formation. SPARC is representative of non-structural matricellular proteins and is of significant importance due to its enhanced expression in many cancers. Both cancer cells and stromal cells can express SPARC protein, with SPARC mRNA visualized in these cells by in situ hybridization[@b26]. In this study, cytoplasmic SPARC expression was only elevated in a few poorly differentiated esophageal SCC and immunostaining signals were generally localized in carcinoma cells at the invasive front. This expression pattern was very similar to that of laminin-5 γ~2~ chain. In contrast, SPARC expression was elevated in the majority of stromal fibroblasts, displaying a strong profile along the negative background of cancer cells.

SPARC possibly influences tumor invasion and metastasis by altering the cytoskeletal structure, thereby affecting cellular adhesion. In addition, the expression of SPARC increases MMP expression in fibroblasts and monocytes. MMP facilitates the degradation of extracellular matrix components, leading to the increased ability of cancer cell movement related to cancer invasion, metastasis, and prognosis. In the present study, the expression level of SPARC in stromal fibroblasts had a tendency to correlate with pTNM stages. Survival analysis showed that high expression of stromal SPARC was associated with poor prognosis. This observation was consistent with earlier studies reporting a significant correlation between the elevated expression of SPARC mRNA and poor prognosis[@b10].

The expression levels of laminin-5 γ~2~ chain and SPARC were analyzed at different pTNM stages, which are representative of the progression of esophageal SCC. In patients with stage-IIA and -IIB esophageal SCC, the elevated expressions of laminin-5 γ~2~ chain and SPARC were associated with poor survival, suggesting laminin-5 γ~2~ chain and SPARC play important roles in stage-II esophageal SCC. Thus, simultaneous high expression of both laminin-5 γ~2~ chain and SPARC is a strong prognostic indicator for survival of patients with stage-II disease.

Laminin-5 γ~2~ chain and SPARC expressions were enhanced in esophageal SCC and predominantly expressed in cancer cells contacting the stroma at the edge of cancer nests. Although SPARC expression was mostly detected in the stroma, laminin-5 γ~2~ chain expression was detectable in cancer cells located at the edge of cancer nests. It has been reported SPARC interacts with laminin and SPARC expression is related to laminin production [@b19]--[@b21]. However, the relationship between laminin-5 γ~2~ chain expression and SPARC expression has not been investigated. We speculate overexpression of SPARC in esophageal SCC induces laminin-5 γ~2~ chain production, providing a mechanism for SPARC to facilitate the progress and metastasis of esophageal SCC. Further studies are warranted to confirm this hypothesis.

The elevated expressions of laminin-5 γ~2~ chain and SPARC may be indicators of poor prognosis in esophageal SCC patients. As both laminin-5 γ~2~ chain and SPARC function in stage-II esophageal SCC and reflect disease progression, detection of these two glycoproteins may be an indicator of clinical prognosis.

![Survival curves of various groups of patients with esophageal SCC. A, patients with tumors strongly expressing (++) laminin-5 γ~2~ chain had a significantly shorter overall survival time than did those with tumors not expressing (--) and weakly expressing (+) laminin-5 γ~2~ chain (*P* = 0.032). B, patients with tumors strongly expressing (++) SPARC in stromal fibroblasts had a significantly shorter overall survival time than did those with tumors not expressing (--) and weakly expressing (+) SPARC in stromal fibroblasts (*P* = 0.034). C, the overall survival curve of patients with tumor cells expressing SPARC (+/++) in stromal fibroblasts was not statistically different from that of patients with tumor cells not expressing SPARC (--) in stromal fibroblasts (*P* = 0.944). D, patients with stage-III/IV esophageal SCC had significantly shorter overall survival time than did those with stage-IIA/IIB diseases (*P* \< 0.001). E, among patients with stage-IIA/IIB esophageal SCC, patients with tumors strongly expressing (++) laminin-5 γ~2~ chain had significantly shorter overall survival time than did those with tumors not expressing (--) and weakly expressing (+) laminin-5 γ~2~ chain (*P* = 0.023). F, among the patients with stage-III/IV esophageal SCC, the overall survival curve of patients with tumor cells strongly expressing (++) laminin-5 γ~2~ chain was not statistically different from that of patients with tumor cells not expressing (--) and weakly expressing (+) laminin-5 γ~2~ chain (*P* = 0.844). G, among patients with stage-IIA/IIB esophageal SCC, patients with tumors strongly expressing (++) SPARC in stromal fibroblasts had shorter overall survival time than did those with tumors not expressing (--) and weakly expressing (+) SPARC in stromal fibroblasts, but without significant difference (*P* = 0.154). H, among the patients with stage-III/IV esophageal SCC, the overall survival curve of patients with tumor cells strongly expressing (++) SPARC in stromal fibroblasts was not statistically different from that of patients with tumor cells not expressing (--) and weakly expressing (+) SPARC in stromal fibroblasts (*P* = 0.988). I, patients were classified into three groups, according to the expressions of laminin-5 γ~2~ chain and/or SPARC in stromal fibroblasts. In group one, neither laminin-5 γ~2~ chain nor SPARC is highly expressed; in group two, either laminin-5 γ~2~ chain or SPARC is highly expressed; and in group three, both laminin-5 γ~2~ chain and SPARC are highly expressed. Patients within group three had significantly shorter overall survival time than did patients in group one or group two (*P* = 0.001). J, patients with stage-IIA/IIB esophageal SCC in group A were further classified into three groups, according to the expressions of laminin-5 γ~2~ chain and/or SPARC in stromal fibroblasts. Group A1 consists of cases in which neither laminin-5 γ~2~ chain nor SPARC highly expressed, group A2 consists of cases in which either laminin-5 γ~2~ chain or SPARC highly expressed, and group A3 consists of cases in which both laminin-5 γ~2~ chain and SPARC highly expressed. Patients within group A3 had significantly shorter overall survival time than did patients in group A1 or group A2 (*P* \< 0.001).](cjc-30-01-069-g002){#cjc-30-01-069-g002}
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